RE:Durability, Durability, Durability"These impressive results have us well-positioned to leverage Oncolytics' prior positive data and join pelareorep's global development program," said Lars Birgerson, M.D., Ph.D., Adlai Nortye President and Chief Medical Officer.
This statement confirms what I had previously posted regarding Adlai Nortye's clinical trial data in a Chinese population as strengthening any approval submission of pelareorep in metastatic breast cancer, since it contributes to the diversity that the FDA and EMA have been seeking in clinical trial populations, especially when it involves I/O agents and their effective montherapy benefit.
And the ability of pelareorep to be able to demonstrate durability in this population of breast cancer patients is of particular significance.
Of even greater significance is the achieved efficacy and durability of pelareorep in combination with other I/O agents, such immune checkpoint inhibitors, for example
And as Lars Birgerson stated .. "With no SAEs reported, the data suggests the favorable safety and potent anti-cancer activity displayed by the studied combination in North American HR+/HER2- breast cancer patients extends to the Chinese population. There are also promising signs of pelareorep-paclitaxel combination therapy driving durable clinical benefit, with one patient notably still on study for nearly a year while maintaining a PR. We look forward to further characterizing the efficacy and durability of the studied combination as data from the trial mature and to continuing our collaboration with Oncolytics."